NSEGeneral Updates2d ago · 2 Sept 2026, 06:19 pm
General Updates
AstraZeneca Pharma India Limited · ASTRAZEN
✦ AI SummaryESG
AstraZeneca Pharma India Limited has informed the Exchange about General Updates, disclosing an ESG rating of 64 from Crisil ESG Ratings & Analytics Limited for fiscal year 2026.
Analysis Scores
Earnings Impact1/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact1/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
Attachments (1)
📄pdf
Download →
ASTRAZEN_02092026181904_Intimation_ESG_Rating_-_Crisil_-_Fiscal_2026.pdf
View document text
September 2, 2026
The Manager – Listing
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai - 400001
The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400051
Dear Sirs/ Madam
Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 – Disclosure of ESG Rating
With reference to the captioned subject, please note that Crisil ESG Ratings & Analytics Limited
(‘Crisil ESG Ratings’) has assigned an Environmental, Social, and Governance (‘ESG’) rating of 64 for
the Company based on publicly available information pertaining to fiscal year 2026.
Please note that the Company has not engaged Crisil ESG Ratings. Crisil ESG Ratings has
independently prepared their reporting based on publicly available information of the Company.
Kindly take the above information on record.
Thanking you,
For AstraZeneca Pharma India Limited
Tanya Sanish
Company Secretary & Compliance Officer